STOCK TITAN
  1. Home
  2. News
  3. NXGL

Nexgel Inc - NXGL STOCK NEWS

Welcome to our dedicated news page for Nexgel (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nexgel's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nexgel's position in the market.

News
NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024
Rhea-AI Summary
NEXGEL, Inc. to present at the Planet MicroCap Showcase: VEGAS 2024 on May 1 & 2, 2024. The CEO, Adam Levy, will be presenting at the event. NEXGEL is a leading provider of medical and OTC products, including hydrogels for healthcare and consumer applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences
-
News
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Rhea-AI Summary
NEXGEL, Inc. reported a record year in 2023 with nearly 100% revenue growth driven by branded products and contract manufacturing. The company expanded its operational infrastructure, secured key partnerships, and made strategic investments for future growth. Financially, revenue for 2023 was $4.1 million, a 99.7% increase from 2022, with gross profit margin improving to 15.2%. Despite revenue growth, cost of revenues and selling, general, and administrative expenses also increased. NEXGEL ended 2023 with a net loss of $3.2 million but had $2.7 million in cash. The company expects first quarter revenue of $1.25 million, excluding a non-refundable deposit from AbbVie. Overall, NEXGEL is positioning itself for significant growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.95%
Tags
none
-
News
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
Rhea-AI Summary
NEXGEL, Inc. reschedules its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET due to the Good Friday holiday closure. CEO Adam Levy aims to enhance visibility and convenience for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
earnings
News
NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
Rhea-AI Summary
NEXGEL, Inc. will report its financial results for Q4 and full year 2023 on March 28, 2024. The Company specializes in medical and OTC products, including hydrogels. A conference call will follow the release of financial results at 4:30 P.M. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences earnings
-
News
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
Rhea-AI Summary
NEXGEL, Inc. announced that CEO Adam Levy will present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th, 2024. NEXGEL is a prominent provider of medical and OTC products, specializing in hydrogels for healthcare and consumer use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.53%
Tags
conferences
-
News
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders
Rhea-AI Summary
NEXGEL, Inc. announces a registered direct offering of common stock and warrants, raising approximately $975,000 for additional working capital. Insiders, including management and the Board of Directors, participated in the offering to support the company's growth opportunities. The offering is facilitated by Alere Financial Partners, LLC, and is made under the Company's shelf registration statement on Form S-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.83%
Tags
offering
News
NEXGEL to Present at The Microcap Conference, January 30th through February 1st
Rhea-AI Summary
NEXGEL, Inc. announced that its CEO will be participating in The Microcap Conference from January 30th to February 1st. The company will present on January 31st and February 1st, and management will be available for 1x1 meetings. Interested parties can register to attend and schedule meetings via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
-
News
NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) announces a 12,000 square foot expansion of its CG Converting and Packaging facility in Granbury, Texas to support expected growth in product demand from new strategic partnerships and its own branded products. The expansion is funded by the landlord and will be completed in the second quarter of 2024. The company is purchasing new automation equipment to support the growth in product demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
News
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) partners with STADA Arzneimittel AG to distribute and commercialize consumer health OTC products in North America in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
partnership
News
NEXGEL Acquires Kenkoderm Psoriasis Skincare Line
Rhea-AI Summary
NEXGEL, Inc. (NASDAQ: NXGL) acquires Kenkoderm, a skincare product company focusing on treating Psoriasis symptoms. Kenkoderm is profitable and expected to boost NEXGEL's revenue and margins. The acquisition aims to optimize marketing and supply chain operations for further growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
acquisition
Stock NXGL logo
Nexgel Inc

Nasdaq:NXGL

NXGL Rankings

#5286 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NXGL Stock Data

13.58M
4.93M
22.82%
2.03%
0.42%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States
Langhorne

About NXGL

nexgel advanced hydrogel solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and fda-approved for the hospital wound care market, and is now being deployed against consumer otc, rx, medical device and cosmetic applications.